Evaluation of the economic benefits, administration times, and patient preferences associated with the use of biotechnological drugs administered subcutaneously and intravenously in patients with cancer: a systematic review

References

• Organización Mundial de la Salud/OMS. Cáncer [Internet]. 2018. p. 1–7. Available from: https://www.who.int/es/news-room/fact-sheets/detail/cancer
   Google Scholar
• World Health Organization. Globocan 2020 [Internet]. WHO Chron. 2020. Available from: https://gco.iarc.fr/today/data/factsheets/populations/900-world-fact-sheets.pdf
   Google Scholar
• Knaul FM, Garcia PJ, Gospodarowicz M, et al. The Lancet commission on cancer and health systems: harnessing synergies to achieve solutions. Lancet. 2021;398(10306):1114–1116. doi: 10.1016/S0140-6736(21)01895-X
   PubMed Web of Science ®Google Scholar
• Hofmarcher T, Lindgren P, Wilking N, et al. The cost of cancer in Europe 2018. Eur J Cancer. 2020;129:41–49. doi: 10.1016/j.ejca.2020.01.011
   PubMed Web of Science ®Google Scholar
• Mariotto AB, Enewold L, Zhao J, et al. Medical care costs associated with cancer survivorship in the United States. Cancer epidemiology biomarkers and prevention;2020; 29(7): 1304–1312. doi: 10.1158/1055-9965
   Google Scholar
• Jackisch C, Kim SB, Semiglazov V, et al. Subcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: updated results from the phase III HannaH study. Ann Oncol. 2015;26(2):320–325. doi: 10.1093/annonc/mdu524
   PubMed Web of Science ®Google Scholar
• Dent S, Ammendolea C, Christofides A, et al. A multidisciplinary perspective on the subcutaneous administration of trastuzumab in HER2-positive breast cancer. Curr Oncol. 2019;26:e70–e80. doi: 10.3747/co.26.4220
   PubMed Web of Science ®Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. BMJ Publishing Group; 2021 372:n71. doi: 10.1136/bmj.n71
   PubMed Web of Science ®Google Scholar
• Ofman JJ, Sullivan SD, Neumann PJ. Examining the value and quality of health economic analyses: implications of utilizing the QHES. J Managed Care Pharm. 2003;9(1):53–61. doi: 10.18553/jmcp.2003.9.1.53
   Google Scholar
• Higgins J, Green S. Manual Cochrane de Revisiones Sistemáticas de Intervenciones, versión 5.1.0 [actualizada en marzo de 2011]. In: Higgins J, Green S, editors. Barcelona: Centro Cochrane Iberoamericano; 2012. https://es.cochrane.org/sites/es.cochrane.org/files/uploads/Manual_Cochrane_510_reduit.pdf
   Google Scholar
• National Heart Lung and BI (NHLBI). Quality assessment tool for observational cohort and cross-sectional studies [Internet]. Bethesda, MD: National Institutes of Health, Department of Health and Human Services. 2014. p. 1–4. Available from: https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools
   Google Scholar
• Downes MJ, Brennan ML, Williams HC, et al. Development of a critical appraisal tool to assess the quality of cross-sectional studies (AXIS). BMJ Open. 2016;6(12):1–7. doi: 10.1136/bmjopen-2016-011458
   Web of Science ®Google Scholar
• Elsamany S, Elsisi GH, Hassanin F, et al. Budget impact analysis of subcutaneous trastuzumab compared to intravenous trastuzumab in Saudi HER2-positive breast cancer patients. Expert Rev Pharmacoecon Outcomes Res. 2021;21(3):511–518. doi: 10.1080/14737167.2021.1860024
   PubMed Web of Science ®Google Scholar
• Sánchez OD, Gutiérrez A, Do Pazo F, et al. Comparative cost analysis of intravenous and subcutaneous administration of rituximab in lymphoma patients. Clinicoecon Outcomes Res. 2019;11:695–701. doi: 10.2147/CEOR.S212257
   PubMed Web of Science ®Google Scholar
• Stewart D, Boudreault J, Maturi B, et al. Evaluation of subcutaneous rituximab administration impacts on Canadian systemic therapy suites. Value Health. 2018;21:S250. doi: 10.1016/j.jval.2018.04.1692
   Web of Science ®Google Scholar
• North RT, Harvey VJ, Cox LC, et al. Medical resource utilization for administration of trastuzumab in a New Zealand oncology outpatient setting: a time and motion study. Clinicoecon Outcomes Res. 2015;7:423–430. doi: 10.2147/CEOR.S85599
   PubMed Web of Science ®Google Scholar
• Mihajlovic J, Bax P, van Breugel E, et al. Microcosting study of rituximab subcutaneous injection versus intravenous infusion. Clin Ther. 2017;39(6):1221–1232.e4. doi: 10.1016/j.clinthera.2017.05.342
   PubMed Web of Science ®Google Scholar
• Franken MG, Kanters TA, Coenen JL, et al. Potential cost savings owing to the route of administration of oncology drugs: a microcosting study of intravenous and subcutaneous administration of trastuzumab and rituximab in the Netherlands. Anticancer Drugs. 2018;29(8):791–801. doi: 10.1097/CAD.0000000000000648
   PubMed Web of Science ®Google Scholar
• Farolfi A, Silimbani P, Gallegati D, et al. Resource utilization and cost saving analysis of subcutaneous versus intravenous trastuzumab in early breast cancer patients. Oncotarget. 2017;8(46):81343–81349. doi: 10.18632/oncotarget.18527
   PubMedGoogle Scholar
• Simoens S, Vulto AG, Dylst P. Simulating costs of intravenous biosimilar trastuzumab vs. subcutaneous reference trastuzumab in adjuvant HER2-positive breast cancer: a Belgian case study. Pharmaceuticals (Basel). 2021;14(5):450. doi: 10.3390/ph14050450
   PubMedGoogle Scholar
• Olofsson S, Norrlid H, Karlsson E, et al. Societal cost of subcutaneous and intravenous trastuzumab for HER2-positive breast cancer - an observational study prospectively recording resource utilization in a Swedish healthcare setting. Breast. 2016;29:140–146.
   PubMed Web of Science ®Google Scholar
• Tjalma WAA, Van den Mooter T, Mertens T, et al. Subcutaneous trastuzumab (Herceptin) versus intravenous trastuzumab for the treatment of patients with HER2-positive breast cancer: a time, motion and cost assessment study in a lean operating day care oncology unit. Eur J Obstet Gynecol Reprod Biol. 2018;221:46–51. doi: 10.1016/j.ejogrb.2017.12.006
   PubMed Web of Science ®Google Scholar
• Rule S, Collins GP, Samanta K. Subcutaneous vs intravenous rituximab in patients with non-Hodgkin lymphoma: a time and motion study in the United Kingdom. J Med Econ. 2014;17(7):459–468. doi: 10.3111/13696998.2014.914033
   PubMedGoogle Scholar
• Altini M, Gentili N, Balzi W, et al. The challenge of sustainability in healthcare systems: economic and organizational impact of subcutaneous formulations for rituximab and trastuzumab in onco-hematology. Expert Rev Pharmacoecon Outcomes Res. 2021;21(3):503–509. doi: 10.1080/14737167.2020.1764353
   PubMed Web of Science ®Google Scholar
• Ponzetti C, Canciani M, Farina M, et al. Potential resource and cost saving analysis of subcutaneous versus intravenous administration for rituximab in non-Hodgkin’s lymphoma and for trastuzumab in breast cancer in 17 Italian hospitals based on a systematic survey. Clinicoecon Outcomes Res. 2016;8:227–233. doi: 10.2147/CEOR.S97319
   PubMed Web of Science ®Google Scholar
• Kading M, Beck B. Cost analysis of daratumumab therapy: is there a cost benefit to using the recently approved subcutaneous product versus the IV product? J Oncol Pharm Pract. 2021;27(4):978–979. doi: 10.1177/1078155221993218
   PubMed Web of Science ®Google Scholar
• O’Brien GL, Cooke K, O’Mahony C, et al. Cost minimisation analysis of intravenous or subcutaneous trastuzumab treatment in patients with HER2-positive breast cancer in Ireland. J Oncol Pharm Pract. 2019;25:63–64. doi: 10.1016/j.clbc.2019.01.011
   Google Scholar
• Mylonas C, Skroumpelos A, Fountzilas G, et al. Cost minimization analysis of herceptin subcutaneous versus herceptin intravenous treatment for patients with HER2+ breast cancer in Greece. J Cancer Policy. 2017;13:11–17. doi: 10.1016/j.jcpo.2017.05.001
   Google Scholar
• Lopez-Vivanco G, Salvador J, Diez R, et al. Cost minimization analysis of treatment with intravenous or subcutaneous trastuzumab in patients with HER2-positive breast cancer in Spain. Clin Transl Oncol. 2017;19(12):1454–1461. doi: 10.1007/s12094-017-1684-4
   PubMed Web of Science ®Google Scholar
• Rojas L, Muñiz S, Medina L, et al. Cost-minimization analysis of subcutaneous versus intravenous trastuzumab administration in Chilean patients with HER2-positive early breast cancer. Plos One. 2020;15(2):1–12. doi: 10.1371/journal.pone.0227961
   Web of Science ®Google Scholar
• Olsen J, Jensen KF, Olesen DS, et al. Costs of subcutaneous and intravenous administration of trastuzumab for patients with HER2-positive breast cancer. J Comp Eff Res. 2018;7(5):411–419. doi: 10.2217/cer-2017-0048
   PubMed Web of Science ®Google Scholar
• Hedayati E, Fracheboud L, Srikant V, et al. Economic benefits of subcutaneous trastuzumab administration: a single institutional study from Karolinska University Hospital in Sweden. Plos One. 2019;14(2):e0211783. doi: 10.1371/journal.pone.0211783
   PubMed Web of Science ®Google Scholar
• Lugtenburg P, Avivi I, Berenschot H, et al. Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study. Haematologica. 2017;102(11):1913–1922. doi: 10.3324/haematol.2017.173583
   PubMed Web of Science ®Google Scholar
• Barbee MS, Harvey RD, Lonial S, et al. Subcutaneous versus intravenous bortezomib: efficiency practice variables and patient preferences. Ann Pharmacother. 2013;47(9):1136–1142. doi: 10.1177/1060028013503122
   PubMed Web of Science ®Google Scholar
• Usmani S, Mateos M-V, Hungria V, et al. Greater treatment satisfaction in patients Receiving subcutaneous (SC) versus intravenous (IV) daratumumab (DARA) for Relapsed or Refractory multiple myeloma (RRMM): COLUMBA. Clin Lymphoma Myeloma Leuk. 2019;19(10):e247–e248. doi: 10.1016/j.clml.2019.09.410
   PubMed Web of Science ®Google Scholar
• Pivot X, Spano JP, Espie M, et al. Patients’ preference of trastuzumab administration (subcutaneous versus intravenous) in HER2-positive metastatic breast cancer: results of the randomised MetaspHer study. Eur J Cancer. 2017;82:230–236. doi: 10.1016/j.ejca.2017.05.009
   PubMed Web of Science ®Google Scholar
• Assouline S, Buccheri V, Delmer A, et al. Pharmacokinetics and safety of subcutaneous rituximab plus fludarabine and cyclophosphamide for patients with chronic lymphocytic leukaemia. Br J Clin Pharmacol. 2015;80(5):1001–1009. doi: 10.1111/bcp.12662
   PubMed Web of Science ®Google Scholar
• Ciruelos EM, Montano A, Rodriguez CA, et al. Phase III study to evaluate patient’s preference of subcutaneous versus intravenous trastuzumab in HER2-positive metastatic breast cancer patients: results from the ChangHER study (GEICAM/2012-07). Eur J Cancer Care (Engl). 2020;29(4):e13253. doi: 10.1111/ecc.13253
   PubMed Web of Science ®Google Scholar
• Rummel M, Kim TM, Aversa F, et al. Preference for subcutaneous or intravenous administration of rituximab among patients with untreated CD20+ diffuse large B-cell lymphoma or follicular lymphoma: results from a prospective, randomized, open-label, crossover study (PrefMab). Ann Oncol. 2017;28(4):836–842. doi: 10.1093/annonc/mdw685
   PubMed Web of Science ®Google Scholar
• Pivot X, Gligorov J, Muller V, et al. Patients’ preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study. Ann Oncol. 2014;25(10):1979–1987. doi: 10.1093/annonc/mdu364
   PubMed Web of Science ®Google Scholar
• Iida S, Ishikawa T, Min CK, et al. Subcutaneous daratumumab in Asian patients with heavily pretreated multiple myeloma: subgroup analyses of the noninferiority, phase 3 COLUMBA study. Ann Hematol. 2021;100(4):1065–1077. doi: 10.1007/s00277-021-04405-2
   PubMed Web of Science ®Google Scholar
• Lazaro Cebas A, Cortijo Cascajares S, Pablos Bravo S, et al. Subcutaneous versus intravenous administration of trastuzumab: preference of HER2+ breast cancer patients and financial impact of its use. J Buon. 2017;22(2):334–339.
   PubMed Web of Science ®Google Scholar
• Pivot X, Gligorov J, Müller V, et al. Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study. Lancet Oncol. 2013;14(10):962–970. doi: 10.1016/S1470-2045(13)70383-8
   PubMed Web of Science ®Google Scholar
• De Cock E, Pivot X, Hauser N, et al. A time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER2-positive early breast cancer. Cancer Med. 2016;5(3):389–397. doi: 10.1002/cam4.573
   PubMed Web of Science ®Google Scholar
• Slavcev M, Spinelli A, Absalon E, et al. Results of a time and motion survey regarding subcutaneous versus intravenous administration of daratumumab in patients with relapsed or refractory multiple myeloma. Clinicoecon Outcomes Res. 2021;13:465–473. doi: 10.2147/CEOR.S302682
   PubMed Web of Science ®Google Scholar
• De Cock E, Kritikou P, Sandoval M, et al. Time savings with rituximab subcutaneous injection versus rituximab intravenous infusion: a time and motion study in eight countries. Plos One. 2016;11(6):e0157957. doi: 10.1371/journal.pone.0157957
   PubMed Web of Science ®Google Scholar
• Harvey MJ, Zhong Y, Morris E, et al. Assessing the transition from intravenous to subcutaneous delivery of rituximab: benefits for payers, health care professionals, and patients with lymphoma. Plos One. 2022;17(1):e0261336. doi: 10.1371/journal.pone.0261336
   PubMed Web of Science ®Google Scholar
• Olivera Changra H, Robles Díaz JF. Costos de la administración intravenosa vs. subcutánea del trastuzumab en pacientes peruanas con cáncer de mama HER2 positivo. Un análisis observacional de los costos directos e indirectos. J Healthc Qual Res. 2022;37(3):147–154. doi: 10.1016/j.jhqr.2021.10.008
   PubMedGoogle Scholar
• Kahan BC, Cro S, Doré CJ, et al. Reducing bias in open-label trials where blinded outcome assessment is not feasible: strategies from two randomised trials. Trials. 2014;15(1):1–6. doi: 10.1186/1745-6215-15-456
   PubMedGoogle Scholar